{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:20:28Z","timestamp":1792653628864,"version":"4.5.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Myelin oligodendrocyte glycoprotein-associated optic neuritis (MOG-ON) is typically a highly treatable condition that responds quickly to treatment with high doses of corticosteroids. We reviewed the cohort of patients with MOG-ON to identify patients who had poor visual outcome after the first attack despite rapid initiation of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Records of all patients diagnosed with MOG-ON seen in a tertiary neuro-ophthalmology practice were reviewed to identify and describe those with poor visual recovery (final visual acuity of 20\/200 or worse in at least one eye) after the first attack despite initiation of treatment within 1 week of symptoms onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Two patients of 36 fulfilled inclusion criteria: both had bilateral severe optic neuritis at presentation, and both were seen within 7 days of symptoms onset and treated immediately with pulse doses of intravenous corticosteroids followed by very-slow oral taper. Plasma exchange (PLEX) was performed 2 weeks after symptoms onset in both patients because of poor response to steroids, followed by monthly intravenous immunoglobulin infusions. Despite the use of all available treatment modalities, final visual outcome was poor in both patients. In both patients, there was enhancement of intracanalicular portion of optic nerve in the worse-seeing eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this cohort of patients with MOG-ON, 2 (5.6%) had very poor visual outcome after the first attack despite immediate initiation of treatment with pulse doses of corticosteroids and subsequent treatment with PLEX. These cases highlight that despite immediate initiation and escalation of treatment, some patients with MOG-ON can have very poor visual outcomes after the initial attack that may be because of the involvement of the intracanalicular portion of the optic nerves.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/wno.0000000000002002","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:06:19Z","timestamp":1697112379000},"page":"178-183","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Poor Visual Outcome After First Attack in a Cohort of Patients With Myelin Oligodendrocyte Glycoprotein-Related Optic Neuritis"],"prefix":"10.1097","volume":"44","author":[{"given":"Armin","family":"Handzic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumana","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Brossard-Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody\u2013positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1007\/s00415-020-10236-4","article-title":"Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis","volume":"268","author":"Lu","year":"2021","journal-title":"J Neurol."},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"In cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/01658107.2015.1084332","article-title":"Anti-MOG (Myelin Oligodendrocyte Glycoprotein)\u2013positive severe optic neuritis with optic disc ischaemia and macular star","volume":"39","author":"Moura","year":"2015","journal-title":"Neuroophthalmol."},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/WNO.0000000000000669","article-title":"Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody\u2013associated optic neuritis","volume":"39","author":"Jelcic","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"R8-20250526","first-page":"e14452","article-title":"Myelin oligodendrocyte glycoprotein (MOG) optic neuritis: a case series","volume":"13","author":"Nurul-Ain","year":"2021","journal-title":"Cureus"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1212\/WNL.38.2.175","article-title":"Magnetic resonance imaging of the optic nerve in optic neuritis","volume":"38","author":"Miller","year":"1988","journal-title":"Neurology"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0161-6420(96)30429-6","article-title":"Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis","volume":"103","author":"Dunker","year":"1996","journal-title":"Ophthalmology"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"}],"container-title":["Journal of Neuro-Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WNO.0000000000002002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:29:10Z","timestamp":1786033750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/WNO.0000000000002002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/wno.0000000000002002","relation":{},"ISSN":["1070-8022"],"issn-type":[{"value":"1070-8022","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}